BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28422716)

  • 1. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
    Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
    Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
    Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC
    PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
    Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
    Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
    BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
    J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
    Li N; Yao QM; Gale RP; Li JL; Li LD; Zhao XS; Jiang H; Jiang Q; Jiang B; Shi HX; Chen SS; Liu KY; Huang XJ; Ruan GR
    Leuk Res; 2015 May; 39(5):510-4. PubMed ID: 25746303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
    Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
    Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
    Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
    Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
    Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
    PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
    Kourie HR; Ameye L; Paesmans M; Bron D
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
    Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
    Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
    Martin S; Wright CM; Scott LM
    Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
    Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
    Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.